Wilmington, MA, United States of America

Thomas Boyajian

This inventor holds 19 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Dusa Pharmaceuticals, Inc., Intrinsic Therapeutics, Inc., Takeda Pharmaceutical Company Limited. Active years: 2009-2026.

USPTO Granted Patents = 19 

% Patents Active = 94.7

 

 

Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 302(Granted Patents)


Company Filing History:


Years Active: 2009-2026

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents

Title: The Inventor Thomas Boyajian: Pioneering Innovations in Wilmington

Introduction: Thomas Boyajian, a distinguished inventor hailing from Wilmington, MA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Boyajian's latest patents showcase his ingenuity and forward-thinking approach to problem-solving in various industries, including telecommunications, robotics, and renewable energy.

Career Highlights: With a career spanning over two decades, Boyajian has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing cutting-edge solutions. His work has not only revolutionized existing technologies but has also paved the way for new advancements in the industry.

Collaborations: Throughout his career, Boyajian has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His ability to work seamlessly in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: Thomas Boyajian's passion for innovation and his relentless drive to push the boundaries of what is possible have solidified his position as a trailblazing inventor in Wilmington and beyond. His work continues to inspire future generations of inventors to think boldly and create fearlessly.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…